Загрузка...
Efficacy and Safety of Treating Stage 2 Systolic Hypertension With Olmesartan and Olmesartan/HCTZ: Results of an Open‐Label Titration Study
This study investigated an aggressive treatment program for stage 2 systolic hypertension (pretreatment systolic blood pressure [SBP] ≥160 mm Hg) using the angiotensin receptor blocker olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ). In this open‐label, 16‐week trial, 170 subjects received...
Сохранить в:
| Опубликовано в: : | J Clin Hypertens (Greenwich) |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Le Jacq
2007
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8109941/ https://ncbi.nlm.nih.gov/pubmed/17215657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1524-6175X.2007.5713.x |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|